nodes	percent_of_prediction	percent_of_DWPC	metapath
Morphine—UGT1A8—Mycophenolate mofetil—psoriasis	0.222	0.298	CbGbCtD
Morphine—UGT2B7—Mycophenolic acid—psoriasis	0.0946	0.127	CbGbCtD
Morphine—UGT1A1—Mycophenolic acid—psoriasis	0.0818	0.11	CbGbCtD
Morphine—UGT2B7—Mycophenolate mofetil—psoriasis	0.0529	0.0711	CbGbCtD
Morphine—UGT1A1—Mycophenolate mofetil—psoriasis	0.0457	0.0614	CbGbCtD
Morphine—CYP2C8—Tazarotene—psoriasis	0.0362	0.0486	CbGbCtD
Morphine—CYP2D6—Hydroxyurea—psoriasis	0.0163	0.0219	CbGbCtD
Morphine—CYP2C8—Cholecalciferol—psoriasis	0.0154	0.0208	CbGbCtD
Morphine—CYP2C8—Mycophenolate mofetil—psoriasis	0.0134	0.018	CbGbCtD
Morphine—CYP3A4—Calcitriol—psoriasis	0.0122	0.0163	CbGbCtD
Morphine—CYP2C8—Hydrocortisone—psoriasis	0.0107	0.0144	CbGbCtD
Morphine—CYP2C8—Cyclosporine—psoriasis	0.0101	0.0136	CbGbCtD
Morphine—CYP2D6—Cholecalciferol—psoriasis	0.00985	0.0132	CbGbCtD
Morphine—CYP3A4—Methoxsalen—psoriasis	0.00945	0.0127	CbGbCtD
Morphine—ABCB1—Mycophenolate mofetil—psoriasis	0.00906	0.0122	CbGbCtD
Morphine—ABCB1—Betamethasone—psoriasis	0.00777	0.0105	CbGbCtD
Morphine—ABCB1—Prednisolone—psoriasis	0.00767	0.0103	CbGbCtD
Morphine—ABCB1—Hydrocortisone—psoriasis	0.00727	0.00978	CbGbCtD
Morphine—ABCB1—Prednisone—psoriasis	0.00724	0.00974	CbGbCtD
Morphine—ABCB1—Cyclosporine—psoriasis	0.00687	0.00924	CbGbCtD
Morphine—CYP2C8—Dexamethasone—psoriasis	0.00668	0.00898	CbGbCtD
Morphine—CYP2D6—Cyclosporine—psoriasis	0.00647	0.0087	CbGbCtD
Morphine—CYP3A4—Cholecalciferol—psoriasis	0.00626	0.00842	CbGbCtD
Morphine—CYP3A4—Mycophenolate mofetil—psoriasis	0.00543	0.0073	CbGbCtD
Morphine—CYP3A4—Triamcinolone—psoriasis	0.00543	0.0073	CbGbCtD
Morphine—CYP3A4—Betamethasone—psoriasis	0.00466	0.00626	CbGbCtD
Morphine—CYP3A4—Prednisolone—psoriasis	0.0046	0.00618	CbGbCtD
Morphine—ABCB1—Dexamethasone—psoriasis	0.00452	0.00608	CbGbCtD
Morphine—CYP3A4—Hydrocortisone—psoriasis	0.00436	0.00586	CbGbCtD
Morphine—CYP3A4—Prednisone—psoriasis	0.00434	0.00584	CbGbCtD
Morphine—CYP2D6—Dexamethasone—psoriasis	0.00426	0.00573	CbGbCtD
Morphine—CYP3A4—Cyclosporine—psoriasis	0.00411	0.00553	CbGbCtD
Morphine—ABCB1—Methotrexate—psoriasis	0.00363	0.00489	CbGbCtD
Morphine—CYP3A4—Dexamethasone—psoriasis	0.00271	0.00364	CbGbCtD
Morphine—OPRM1—TCR Signaling Pathway—IL17A—psoriasis	0.000179	0.00566	CbGpPWpGaD
Morphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000175	0.00554	CbGpPWpGaD
Morphine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000172	0.00542	CbGpPWpGaD
Morphine—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000169	0.00535	CbGpPWpGaD
Morphine—OPRL1—Circadian rythm related genes—LEP—psoriasis	0.000167	0.00526	CbGpPWpGaD
Morphine—OPRM1—IL4-mediated signaling events—IL10—psoriasis	0.000164	0.00519	CbGpPWpGaD
Morphine—UGT1A8—Metabolism—NDUFA5—psoriasis	0.000163	0.00514	CbGpPWpGaD
Morphine—OPRK1—Peptide ligand-binding receptors—CCL20—psoriasis	0.000161	0.00507	CbGpPWpGaD
Morphine—OPRM1—IL4-mediated signaling events—IL4—psoriasis	0.00016	0.00504	CbGpPWpGaD
Morphine—OPRK1—GPCR ligand binding—HCAR2—psoriasis	0.000158	0.00499	CbGpPWpGaD
Morphine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	0.000157	0.00495	CbGpPWpGaD
Morphine—OPRL1—Circadian rythm related genes—NOS2—psoriasis	0.000155	0.00491	CbGpPWpGaD
Morphine—OPRD1—G alpha (i) signalling events—CCL20—psoriasis	0.000154	0.00488	CbGpPWpGaD
Morphine—UGT1A1—NRF2 pathway—TGFA—psoriasis	0.000146	0.0046	CbGpPWpGaD
Morphine—OPRL1—Circadian rythm related genes—PPARG—psoriasis	0.000145	0.00458	CbGpPWpGaD
Morphine—UGT2B15—Metabolism—NDUFA5—psoriasis	0.000142	0.00449	CbGpPWpGaD
Morphine—UGT2B4—Metabolism—NDUFA5—psoriasis	0.000142	0.00449	CbGpPWpGaD
Morphine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000139	0.0044	CbGpPWpGaD
Morphine—UGT1A8—Metabolism—CYP2S1—psoriasis	0.000138	0.00437	CbGpPWpGaD
Morphine—CYP2C8—Biological oxidations—CYP2S1—psoriasis	0.000138	0.00435	CbGpPWpGaD
Morphine—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000137	0.00434	CbGpPWpGaD
Morphine—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	0.000136	0.00429	CbGpPWpGaD
Morphine—OPRM1—Peptide ligand-binding receptors—CCL20—psoriasis	0.000136	0.00429	CbGpPWpGaD
Morphine—OPRK1—G alpha (i) signalling events—CCL20—psoriasis	0.000135	0.00428	CbGpPWpGaD
Morphine—OPRM1—GPCR ligand binding—HCAR2—psoriasis	0.000133	0.00422	CbGpPWpGaD
Morphine—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	0.000132	0.00418	CbGpPWpGaD
Morphine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000128	0.00404	CbGpPWpGaD
Morphine—OPRL1—Signaling Pathways—HCAR2—psoriasis	0.000128	0.00404	CbGpPWpGaD
Morphine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	0.000125	0.00396	CbGpPWpGaD
Morphine—OPRL1—GPCR downstream signaling—CCL20—psoriasis	0.000124	0.00391	CbGpPWpGaD
Morphine—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000123	0.00388	CbGpPWpGaD
Morphine—UGT2B15—Metabolism—CYP2S1—psoriasis	0.000121	0.00382	CbGpPWpGaD
Morphine—UGT2B4—Metabolism—CYP2S1—psoriasis	0.000121	0.00382	CbGpPWpGaD
Morphine—OPRM1—TCR Signaling Pathway—CD8A—psoriasis	0.00012	0.00381	CbGpPWpGaD
Morphine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	0.000117	0.00371	CbGpPWpGaD
Morphine—OPRL1—Peptide ligand-binding receptors—CXCL8—psoriasis	0.000116	0.00366	CbGpPWpGaD
Morphine—OPRM1—G alpha (i) signalling events—CCL20—psoriasis	0.000114	0.00362	CbGpPWpGaD
Morphine—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.000113	0.00357	CbGpPWpGaD
Morphine—OPRL1—Signaling by GPCR—CCL20—psoriasis	0.000112	0.00355	CbGpPWpGaD
Morphine—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.000112	0.00352	CbGpPWpGaD
Morphine—OPRL1—Signaling Pathways—TAGAP—psoriasis	0.000111	0.0035	CbGpPWpGaD
Morphine—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.00011	0.00346	CbGpPWpGaD
Morphine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	0.000108	0.00342	CbGpPWpGaD
Morphine—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000108	0.0034	CbGpPWpGaD
Morphine—OPRL1—Circadian rythm related genes—JUN—psoriasis	0.000103	0.00325	CbGpPWpGaD
Morphine—ABCB1—Allograft Rejection—HLA-C—psoriasis	0.000102	0.00322	CbGpPWpGaD
Morphine—OPRD1—GPCR downstream signaling—HCAR2—psoriasis	0.000102	0.00321	CbGpPWpGaD
Morphine—ABCB1—Allograft Rejection—IL13—psoriasis	0.000101	0.0032	CbGpPWpGaD
Morphine—OPRL1—G alpha (i) signalling events—CXCL8—psoriasis	9.77e-05	0.00309	CbGpPWpGaD
Morphine—OPRD1—GPCR ligand binding—CCL20—psoriasis	9.35e-05	0.00295	CbGpPWpGaD
Morphine—OPRM1—TCR Signaling Pathway—NFKBIA—psoriasis	9.34e-05	0.00295	CbGpPWpGaD
Morphine—ABCB1—Allograft Rejection—IL17A—psoriasis	9.33e-05	0.00295	CbGpPWpGaD
Morphine—OPRD1—Signaling by GPCR—HCAR2—psoriasis	9.24e-05	0.00292	CbGpPWpGaD
Morphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	9.1e-05	0.00288	CbGpPWpGaD
Morphine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	8.92e-05	0.00282	CbGpPWpGaD
Morphine—OPRK1—GPCR downstream signaling—HCAR2—psoriasis	8.92e-05	0.00282	CbGpPWpGaD
Morphine—ABCB1—Allograft Rejection—IL12B—psoriasis	8.68e-05	0.00274	CbGpPWpGaD
Morphine—ABCB1—Allograft Rejection—HLA-E—psoriasis	8.47e-05	0.00268	CbGpPWpGaD
Morphine—OPRK1—GPCR ligand binding—CCL20—psoriasis	8.2e-05	0.00259	CbGpPWpGaD
Morphine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	8.11e-05	0.00256	CbGpPWpGaD
Morphine—OPRK1—Signaling by GPCR—HCAR2—psoriasis	8.1e-05	0.00256	CbGpPWpGaD
Morphine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	7.89e-05	0.00249	CbGpPWpGaD
Morphine—OPRL1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	7.77e-05	0.00245	CbGpPWpGaD
Morphine—UGT1A3—Metabolism—NDUFA5—psoriasis	7.61e-05	0.00241	CbGpPWpGaD
Morphine—OPRM1—GPCR downstream signaling—HCAR2—psoriasis	7.54e-05	0.00238	CbGpPWpGaD
Morphine—CYP3A4—Biological oxidations—CYP2S1—psoriasis	7.39e-05	0.00234	CbGpPWpGaD
Morphine—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	7.29e-05	0.0023	CbGpPWpGaD
Morphine—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	7.01e-05	0.00221	CbGpPWpGaD
Morphine—OPRM1—GPCR ligand binding—CCL20—psoriasis	6.93e-05	0.00219	CbGpPWpGaD
Morphine—OPRM1—TCR Signaling Pathway—CD4—psoriasis	6.92e-05	0.00219	CbGpPWpGaD
Morphine—OPRM1—Signaling by GPCR—HCAR2—psoriasis	6.85e-05	0.00216	CbGpPWpGaD
Morphine—OPRL1—Circadian rythm related genes—TP53—psoriasis	6.79e-05	0.00215	CbGpPWpGaD
Morphine—UGT1A8—Metabolism—CARM1—psoriasis	6.75e-05	0.00213	CbGpPWpGaD
Morphine—OPRL1—Signaling Pathways—CCL20—psoriasis	6.64e-05	0.0021	CbGpPWpGaD
Morphine—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	6.52e-05	0.00206	CbGpPWpGaD
Morphine—UGT1A3—Metabolism—CYP2S1—psoriasis	6.47e-05	0.00205	CbGpPWpGaD
Morphine—UGT2B7—Metabolism—NDUFA5—psoriasis	6.47e-05	0.00205	CbGpPWpGaD
Morphine—CYP3A4—Tryptophan metabolism—CAT—psoriasis	6.38e-05	0.00202	CbGpPWpGaD
Morphine—ABCB1—Allograft Rejection—IL10—psoriasis	6.34e-05	0.002	CbGpPWpGaD
Morphine—Body temperature increased—Cyclosporine—psoriasis	6.31e-05	0.000281	CcSEcCtD
Morphine—Abdominal pain—Cyclosporine—psoriasis	6.31e-05	0.000281	CcSEcCtD
Morphine—Anxiety—Betamethasone—psoriasis	6.3e-05	0.00028	CcSEcCtD
Morphine—Anxiety—Dexamethasone—psoriasis	6.3e-05	0.00028	CcSEcCtD
Morphine—Vomiting—Mycophenolic acid—psoriasis	6.27e-05	0.000279	CcSEcCtD
Morphine—Discomfort—Dexamethasone—psoriasis	6.25e-05	0.000278	CcSEcCtD
Morphine—Discomfort—Betamethasone—psoriasis	6.25e-05	0.000278	CcSEcCtD
Morphine—Dyspepsia—Hydrocortisone—psoriasis	6.24e-05	0.000278	CcSEcCtD
Morphine—Rash—Mycophenolic acid—psoriasis	6.22e-05	0.000277	CcSEcCtD
Morphine—OPRL1—Circadian rythm related genes—IL6—psoriasis	6.22e-05	0.00196	CbGpPWpGaD
Morphine—Dermatitis—Mycophenolic acid—psoriasis	6.21e-05	0.000276	CcSEcCtD
Morphine—Pain—Prednisolone—psoriasis	6.21e-05	0.000276	CcSEcCtD
Morphine—Hepatitis—Methotrexate—psoriasis	6.21e-05	0.000276	CcSEcCtD
Morphine—OPRM1—TCR Signaling Pathway—JUN—psoriasis	6.19e-05	0.00196	CbGpPWpGaD
Morphine—Urticaria—Mycophenolate mofetil—psoriasis	6.18e-05	0.000275	CcSEcCtD
Morphine—Headache—Mycophenolic acid—psoriasis	6.18e-05	0.000275	CcSEcCtD
Morphine—ABCB1—Allograft Rejection—IL4—psoriasis	6.17e-05	0.00195	CbGpPWpGaD
Morphine—Decreased appetite—Hydrocortisone—psoriasis	6.17e-05	0.000274	CcSEcCtD
Morphine—Abdominal pain—Mycophenolate mofetil—psoriasis	6.15e-05	0.000274	CcSEcCtD
Morphine—Body temperature increased—Mycophenolate mofetil—psoriasis	6.15e-05	0.000274	CcSEcCtD
Morphine—Urinary tract disorder—Methotrexate—psoriasis	6.13e-05	0.000273	CcSEcCtD
Morphine—Gastrointestinal disorder—Hydrocortisone—psoriasis	6.12e-05	0.000272	CcSEcCtD
Morphine—Fatigue—Hydrocortisone—psoriasis	6.12e-05	0.000272	CcSEcCtD
Morphine—Vision blurred—Prednisone—psoriasis	6.09e-05	0.000271	CcSEcCtD
Morphine—Urethral disorder—Methotrexate—psoriasis	6.09e-05	0.000271	CcSEcCtD
Morphine—Musculoskeletal discomfort—Triamcinolone—psoriasis	6.08e-05	0.000271	CcSEcCtD
Morphine—Pain—Hydrocortisone—psoriasis	6.07e-05	0.00027	CcSEcCtD
Morphine—Oedema—Dexamethasone—psoriasis	6.06e-05	0.00027	CcSEcCtD
Morphine—Anaphylactic shock—Dexamethasone—psoriasis	6.06e-05	0.00027	CcSEcCtD
Morphine—Oedema—Betamethasone—psoriasis	6.06e-05	0.00027	CcSEcCtD
Morphine—Anaphylactic shock—Betamethasone—psoriasis	6.06e-05	0.00027	CcSEcCtD
Morphine—Insomnia—Triamcinolone—psoriasis	6.04e-05	0.000269	CcSEcCtD
Morphine—ABCB1—Allograft Rejection—HLA-B—psoriasis	6.03e-05	0.00191	CbGpPWpGaD
Morphine—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	6.03e-05	0.0019	CbGpPWpGaD
Morphine—Infection—Dexamethasone—psoriasis	6.02e-05	0.000268	CcSEcCtD
Morphine—Infection—Betamethasone—psoriasis	6.02e-05	0.000268	CcSEcCtD
Morphine—Ill-defined disorder—Prednisone—psoriasis	6e-05	0.000267	CcSEcCtD
Morphine—Paraesthesia—Triamcinolone—psoriasis	6e-05	0.000267	CcSEcCtD
Morphine—Feeling abnormal—Prednisolone—psoriasis	5.98e-05	0.000266	CcSEcCtD
Morphine—Visual impairment—Methotrexate—psoriasis	5.98e-05	0.000266	CcSEcCtD
Morphine—Anaemia—Prednisone—psoriasis	5.98e-05	0.000266	CcSEcCtD
Morphine—Shock—Dexamethasone—psoriasis	5.96e-05	0.000265	CcSEcCtD
Morphine—Shock—Betamethasone—psoriasis	5.96e-05	0.000265	CcSEcCtD
Morphine—OPRM1—TCR Signaling Pathway—NFKB1—psoriasis	5.96e-05	0.00188	CbGpPWpGaD
Morphine—Dyspnoea—Triamcinolone—psoriasis	5.95e-05	0.000265	CcSEcCtD
Morphine—Nervous system disorder—Betamethasone—psoriasis	5.94e-05	0.000264	CcSEcCtD
Morphine—Nervous system disorder—Dexamethasone—psoriasis	5.94e-05	0.000264	CcSEcCtD
Morphine—Agitation—Prednisone—psoriasis	5.94e-05	0.000264	CcSEcCtD
Morphine—Thrombocytopenia—Dexamethasone—psoriasis	5.93e-05	0.000264	CcSEcCtD
Morphine—Thrombocytopenia—Betamethasone—psoriasis	5.93e-05	0.000264	CcSEcCtD
Morphine—OPRL1—GPCR ligand binding—CXCL8—psoriasis	5.92e-05	0.00187	CbGpPWpGaD
Morphine—Tachycardia—Betamethasone—psoriasis	5.91e-05	0.000263	CcSEcCtD
Morphine—Tachycardia—Dexamethasone—psoriasis	5.91e-05	0.000263	CcSEcCtD
Morphine—UGT2B15—Metabolism—CARM1—psoriasis	5.9e-05	0.00186	CbGpPWpGaD
Morphine—UGT2B4—Metabolism—CARM1—psoriasis	5.9e-05	0.00186	CbGpPWpGaD
Morphine—Hypersensitivity—Cyclosporine—psoriasis	5.88e-05	0.000262	CcSEcCtD
Morphine—Dyspepsia—Triamcinolone—psoriasis	5.88e-05	0.000261	CcSEcCtD
Morphine—Nausea—Mycophenolic acid—psoriasis	5.86e-05	0.000261	CcSEcCtD
Morphine—Hyperhidrosis—Betamethasone—psoriasis	5.86e-05	0.000261	CcSEcCtD
Morphine—Hyperhidrosis—Dexamethasone—psoriasis	5.86e-05	0.000261	CcSEcCtD
Morphine—Feeling abnormal—Hydrocortisone—psoriasis	5.84e-05	0.00026	CcSEcCtD
Morphine—Malaise—Prednisone—psoriasis	5.83e-05	0.000259	CcSEcCtD
Morphine—Vertigo—Prednisone—psoriasis	5.81e-05	0.000258	CcSEcCtD
Morphine—Eye disorder—Methotrexate—psoriasis	5.8e-05	0.000258	CcSEcCtD
Morphine—Gastrointestinal pain—Hydrocortisone—psoriasis	5.8e-05	0.000258	CcSEcCtD
Morphine—Syncope—Prednisone—psoriasis	5.8e-05	0.000258	CcSEcCtD
Morphine—Anorexia—Betamethasone—psoriasis	5.78e-05	0.000257	CcSEcCtD
Morphine—Anorexia—Dexamethasone—psoriasis	5.78e-05	0.000257	CcSEcCtD
Morphine—Urticaria—Prednisolone—psoriasis	5.77e-05	0.000257	CcSEcCtD
Morphine—Fatigue—Triamcinolone—psoriasis	5.76e-05	0.000256	CcSEcCtD
Morphine—Hypersensitivity—Mycophenolate mofetil—psoriasis	5.74e-05	0.000255	CcSEcCtD
Morphine—Asthenia—Cyclosporine—psoriasis	5.73e-05	0.000255	CcSEcCtD
Morphine—Pain—Triamcinolone—psoriasis	5.71e-05	0.000254	CcSEcCtD
Morphine—Loss of consciousness—Prednisone—psoriasis	5.68e-05	0.000253	CcSEcCtD
Morphine—Hypotension—Betamethasone—psoriasis	5.66e-05	0.000252	CcSEcCtD
Morphine—Hypotension—Dexamethasone—psoriasis	5.66e-05	0.000252	CcSEcCtD
Morphine—Pruritus—Cyclosporine—psoriasis	5.65e-05	0.000251	CcSEcCtD
Morphine—Urticaria—Hydrocortisone—psoriasis	5.63e-05	0.000251	CcSEcCtD
Morphine—Angiopathy—Methotrexate—psoriasis	5.63e-05	0.00025	CcSEcCtD
Morphine—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	5.62e-05	0.00177	CbGpPWpGaD
Morphine—Abdominal pain—Hydrocortisone—psoriasis	5.61e-05	0.000249	CcSEcCtD
Morphine—Body temperature increased—Hydrocortisone—psoriasis	5.61e-05	0.000249	CcSEcCtD
Morphine—Convulsion—Prednisone—psoriasis	5.6e-05	0.000249	CcSEcCtD
Morphine—Mediastinal disorder—Methotrexate—psoriasis	5.59e-05	0.000249	CcSEcCtD
Morphine—ABCB1—Allograft Rejection—HLA-A—psoriasis	5.59e-05	0.00177	CbGpPWpGaD
Morphine—Asthenia—Mycophenolate mofetil—psoriasis	5.59e-05	0.000248	CcSEcCtD
Morphine—Hypertension—Prednisone—psoriasis	5.58e-05	0.000248	CcSEcCtD
Morphine—Chills—Methotrexate—psoriasis	5.57e-05	0.000248	CcSEcCtD
Morphine—Musculoskeletal discomfort—Betamethasone—psoriasis	5.52e-05	0.000246	CcSEcCtD
Morphine—Musculoskeletal discomfort—Dexamethasone—psoriasis	5.52e-05	0.000246	CcSEcCtD
Morphine—Pruritus—Mycophenolate mofetil—psoriasis	5.51e-05	0.000245	CcSEcCtD
Morphine—Arthralgia—Prednisone—psoriasis	5.51e-05	0.000245	CcSEcCtD
Morphine—UGT2B7—Metabolism—CYP2S1—psoriasis	5.5e-05	0.00174	CbGpPWpGaD
Morphine—Feeling abnormal—Triamcinolone—psoriasis	5.5e-05	0.000245	CcSEcCtD
Morphine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	5.5e-05	0.00174	CbGpPWpGaD
Morphine—Anxiety—Prednisone—psoriasis	5.49e-05	0.000244	CcSEcCtD
Morphine—Insomnia—Betamethasone—psoriasis	5.48e-05	0.000244	CcSEcCtD
Morphine—Insomnia—Dexamethasone—psoriasis	5.48e-05	0.000244	CcSEcCtD
Morphine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	5.47e-05	0.000243	CcSEcCtD
Morphine—Diarrhoea—Cyclosporine—psoriasis	5.46e-05	0.000243	CcSEcCtD
Morphine—OPRD1—Signaling Pathways—HCAR2—psoriasis	5.46e-05	0.00172	CbGpPWpGaD
Morphine—Paraesthesia—Dexamethasone—psoriasis	5.44e-05	0.000242	CcSEcCtD
Morphine—Paraesthesia—Betamethasone—psoriasis	5.44e-05	0.000242	CcSEcCtD
Morphine—Discomfort—Prednisone—psoriasis	5.44e-05	0.000242	CcSEcCtD
Morphine—Mental disorder—Methotrexate—psoriasis	5.44e-05	0.000242	CcSEcCtD
Morphine—Malnutrition—Methotrexate—psoriasis	5.4e-05	0.00024	CcSEcCtD
Morphine—Erythema—Methotrexate—psoriasis	5.4e-05	0.00024	CcSEcCtD
Morphine—Hypersensitivity—Prednisolone—psoriasis	5.35e-05	0.000238	CcSEcCtD
Morphine—Dyspepsia—Dexamethasone—psoriasis	5.33e-05	0.000237	CcSEcCtD
Morphine—Dyspepsia—Betamethasone—psoriasis	5.33e-05	0.000237	CcSEcCtD
Morphine—Diarrhoea—Mycophenolate mofetil—psoriasis	5.33e-05	0.000237	CcSEcCtD
Morphine—Urticaria—Triamcinolone—psoriasis	5.31e-05	0.000236	CcSEcCtD
Morphine—Dysgeusia—Methotrexate—psoriasis	5.29e-05	0.000235	CcSEcCtD
Morphine—OPRD1—GPCR downstream signaling—CCL20—psoriasis	5.28e-05	0.00167	CbGpPWpGaD
Morphine—Body temperature increased—Triamcinolone—psoriasis	5.28e-05	0.000235	CcSEcCtD
Morphine—Dizziness—Cyclosporine—psoriasis	5.28e-05	0.000235	CcSEcCtD
Morphine—Oedema—Prednisone—psoriasis	5.28e-05	0.000235	CcSEcCtD
Morphine—Anaphylactic shock—Prednisone—psoriasis	5.28e-05	0.000235	CcSEcCtD
Morphine—Decreased appetite—Dexamethasone—psoriasis	5.27e-05	0.000234	CcSEcCtD
Morphine—Decreased appetite—Betamethasone—psoriasis	5.27e-05	0.000234	CcSEcCtD
Morphine—UGT1A1—Metabolism—NDUFA5—psoriasis	5.26e-05	0.00166	CbGpPWpGaD
Morphine—Infection—Prednisone—psoriasis	5.24e-05	0.000233	CcSEcCtD
Morphine—Gastrointestinal disorder—Dexamethasone—psoriasis	5.23e-05	0.000233	CcSEcCtD
Morphine—Gastrointestinal disorder—Betamethasone—psoriasis	5.23e-05	0.000233	CcSEcCtD
Morphine—Back pain—Methotrexate—psoriasis	5.23e-05	0.000232	CcSEcCtD
Morphine—Hypersensitivity—Hydrocortisone—psoriasis	5.23e-05	0.000232	CcSEcCtD
Morphine—Fatigue—Betamethasone—psoriasis	5.22e-05	0.000232	CcSEcCtD
Morphine—Fatigue—Dexamethasone—psoriasis	5.22e-05	0.000232	CcSEcCtD
Morphine—Shock—Prednisone—psoriasis	5.19e-05	0.000231	CcSEcCtD
Morphine—Pain—Betamethasone—psoriasis	5.18e-05	0.00023	CcSEcCtD
Morphine—Pain—Dexamethasone—psoriasis	5.18e-05	0.00023	CcSEcCtD
Morphine—Nervous system disorder—Prednisone—psoriasis	5.18e-05	0.00023	CcSEcCtD
Morphine—Tachycardia—Prednisone—psoriasis	5.15e-05	0.000229	CcSEcCtD
Morphine—Dizziness—Mycophenolate mofetil—psoriasis	5.15e-05	0.000229	CcSEcCtD
Morphine—Skin disorder—Prednisone—psoriasis	5.13e-05	0.000228	CcSEcCtD
Morphine—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	5.11e-05	0.00161	CbGpPWpGaD
Morphine—Hyperhidrosis—Prednisone—psoriasis	5.1e-05	0.000227	CcSEcCtD
Morphine—Vision blurred—Methotrexate—psoriasis	5.09e-05	0.000227	CcSEcCtD
Morphine—Asthenia—Hydrocortisone—psoriasis	5.09e-05	0.000226	CcSEcCtD
Morphine—Vomiting—Cyclosporine—psoriasis	5.07e-05	0.000226	CcSEcCtD
Morphine—Rash—Cyclosporine—psoriasis	5.03e-05	0.000224	CcSEcCtD
Morphine—Anorexia—Prednisone—psoriasis	5.03e-05	0.000224	CcSEcCtD
Morphine—Dermatitis—Cyclosporine—psoriasis	5.03e-05	0.000224	CcSEcCtD
Morphine—Pruritus—Hydrocortisone—psoriasis	5.02e-05	0.000223	CcSEcCtD
Morphine—Ill-defined disorder—Methotrexate—psoriasis	5.01e-05	0.000223	CcSEcCtD
Morphine—Headache—Cyclosporine—psoriasis	5e-05	0.000222	CcSEcCtD
Morphine—Anaemia—Methotrexate—psoriasis	4.99e-05	0.000222	CcSEcCtD
Morphine—Feeling abnormal—Betamethasone—psoriasis	4.99e-05	0.000222	CcSEcCtD
Morphine—Feeling abnormal—Dexamethasone—psoriasis	4.99e-05	0.000222	CcSEcCtD
Morphine—Gastrointestinal pain—Betamethasone—psoriasis	4.96e-05	0.00022	CcSEcCtD
Morphine—Gastrointestinal pain—Dexamethasone—psoriasis	4.96e-05	0.00022	CcSEcCtD
Morphine—Vomiting—Mycophenolate mofetil—psoriasis	4.95e-05	0.00022	CcSEcCtD
Morphine—OPRD1—Peptide ligand-binding receptors—CXCL8—psoriasis	4.94e-05	0.00156	CbGpPWpGaD
Morphine—Hypersensitivity—Triamcinolone—psoriasis	4.92e-05	0.000219	CcSEcCtD
Morphine—Rash—Mycophenolate mofetil—psoriasis	4.91e-05	0.000218	CcSEcCtD
Morphine—Dermatitis—Mycophenolate mofetil—psoriasis	4.9e-05	0.000218	CcSEcCtD
Morphine—Headache—Mycophenolate mofetil—psoriasis	4.88e-05	0.000217	CcSEcCtD
Morphine—Malaise—Methotrexate—psoriasis	4.87e-05	0.000217	CcSEcCtD
Morphine—Vertigo—Methotrexate—psoriasis	4.86e-05	0.000216	CcSEcCtD
Morphine—Diarrhoea—Hydrocortisone—psoriasis	4.85e-05	0.000216	CcSEcCtD
Morphine—Leukopenia—Methotrexate—psoriasis	4.84e-05	0.000215	CcSEcCtD
Morphine—Urticaria—Dexamethasone—psoriasis	4.81e-05	0.000214	CcSEcCtD
Morphine—Urticaria—Betamethasone—psoriasis	4.81e-05	0.000214	CcSEcCtD
Morphine—Musculoskeletal discomfort—Prednisone—psoriasis	4.81e-05	0.000214	CcSEcCtD
Morphine—Dizziness—Prednisolone—psoriasis	4.8e-05	0.000214	CcSEcCtD
Morphine—OPRD1—Signaling by GPCR—CCL20—psoriasis	4.8e-05	0.00152	CbGpPWpGaD
Morphine—Asthenia—Triamcinolone—psoriasis	4.79e-05	0.000213	CcSEcCtD
Morphine—Body temperature increased—Dexamethasone—psoriasis	4.79e-05	0.000213	CcSEcCtD
Morphine—Abdominal pain—Betamethasone—psoriasis	4.79e-05	0.000213	CcSEcCtD
Morphine—Body temperature increased—Betamethasone—psoriasis	4.79e-05	0.000213	CcSEcCtD
Morphine—Abdominal pain—Dexamethasone—psoriasis	4.79e-05	0.000213	CcSEcCtD
Morphine—OPRK1—Signaling Pathways—HCAR2—psoriasis	4.79e-05	0.00151	CbGpPWpGaD
Morphine—Insomnia—Prednisone—psoriasis	4.77e-05	0.000212	CcSEcCtD
Morphine—Nausea—Cyclosporine—psoriasis	4.74e-05	0.000211	CcSEcCtD
Morphine—Paraesthesia—Prednisone—psoriasis	4.74e-05	0.000211	CcSEcCtD
Morphine—OPRD1—Signaling Pathways—TAGAP—psoriasis	4.73e-05	0.0015	CbGpPWpGaD
Morphine—Pruritus—Triamcinolone—psoriasis	4.73e-05	0.00021	CcSEcCtD
Morphine—Cough—Methotrexate—psoriasis	4.72e-05	0.00021	CcSEcCtD
Morphine—Dizziness—Hydrocortisone—psoriasis	4.69e-05	0.000209	CcSEcCtD
Morphine—Convulsion—Methotrexate—psoriasis	4.68e-05	0.000208	CcSEcCtD
Morphine—Dyspepsia—Prednisone—psoriasis	4.65e-05	0.000207	CcSEcCtD
Morphine—OPRK1—GPCR downstream signaling—CCL20—psoriasis	4.63e-05	0.00146	CbGpPWpGaD
Morphine—Nausea—Mycophenolate mofetil—psoriasis	4.62e-05	0.000206	CcSEcCtD
Morphine—Chest pain—Methotrexate—psoriasis	4.6e-05	0.000205	CcSEcCtD
Morphine—Arthralgia—Methotrexate—psoriasis	4.6e-05	0.000205	CcSEcCtD
Morphine—Decreased appetite—Prednisone—psoriasis	4.59e-05	0.000204	CcSEcCtD
Morphine—Rash—Prednisolone—psoriasis	4.58e-05	0.000204	CcSEcCtD
Morphine—Dermatitis—Prednisolone—psoriasis	4.57e-05	0.000203	CcSEcCtD
Morphine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	4.57e-05	0.000203	CcSEcCtD
Morphine—Fatigue—Prednisone—psoriasis	4.55e-05	0.000202	CcSEcCtD
Morphine—Headache—Prednisolone—psoriasis	4.55e-05	0.000202	CcSEcCtD
Morphine—Discomfort—Methotrexate—psoriasis	4.55e-05	0.000202	CcSEcCtD
Morphine—Constipation—Prednisone—psoriasis	4.51e-05	0.000201	CcSEcCtD
Morphine—Vomiting—Hydrocortisone—psoriasis	4.51e-05	0.000201	CcSEcCtD
Morphine—UGT1A1—Metabolism—CYP2S1—psoriasis	4.47e-05	0.00141	CbGpPWpGaD
Morphine—Rash—Hydrocortisone—psoriasis	4.47e-05	0.000199	CcSEcCtD
Morphine—Dermatitis—Hydrocortisone—psoriasis	4.47e-05	0.000199	CcSEcCtD
Morphine—Confusional state—Methotrexate—psoriasis	4.45e-05	0.000198	CcSEcCtD
Morphine—Headache—Hydrocortisone—psoriasis	4.44e-05	0.000198	CcSEcCtD
Morphine—Dizziness—Triamcinolone—psoriasis	4.42e-05	0.000196	CcSEcCtD
Morphine—Anaphylactic shock—Methotrexate—psoriasis	4.41e-05	0.000196	CcSEcCtD
Morphine—Infection—Methotrexate—psoriasis	4.38e-05	0.000195	CcSEcCtD
Morphine—Feeling abnormal—Prednisone—psoriasis	4.35e-05	0.000193	CcSEcCtD
Morphine—Asthenia—Betamethasone—psoriasis	4.35e-05	0.000193	CcSEcCtD
Morphine—Asthenia—Dexamethasone—psoriasis	4.35e-05	0.000193	CcSEcCtD
Morphine—OPRK1—Peptide ligand-binding receptors—CXCL8—psoriasis	4.33e-05	0.00137	CbGpPWpGaD
Morphine—Nervous system disorder—Methotrexate—psoriasis	4.33e-05	0.000192	CcSEcCtD
Morphine—Thrombocytopenia—Methotrexate—psoriasis	4.32e-05	0.000192	CcSEcCtD
Morphine—Gastrointestinal pain—Prednisone—psoriasis	4.32e-05	0.000192	CcSEcCtD
Morphine—Nausea—Prednisolone—psoriasis	4.31e-05	0.000192	CcSEcCtD
Morphine—Pruritus—Dexamethasone—psoriasis	4.29e-05	0.000191	CcSEcCtD
Morphine—Pruritus—Betamethasone—psoriasis	4.29e-05	0.000191	CcSEcCtD
Morphine—Skin disorder—Methotrexate—psoriasis	4.28e-05	0.000191	CcSEcCtD
Morphine—Hyperhidrosis—Methotrexate—psoriasis	4.26e-05	0.00019	CcSEcCtD
Morphine—Vomiting—Triamcinolone—psoriasis	4.25e-05	0.000189	CcSEcCtD
Morphine—Nausea—Hydrocortisone—psoriasis	4.21e-05	0.000187	CcSEcCtD
Morphine—Rash—Triamcinolone—psoriasis	4.21e-05	0.000187	CcSEcCtD
Morphine—OPRK1—Signaling by GPCR—CCL20—psoriasis	4.21e-05	0.00133	CbGpPWpGaD
Morphine—Dermatitis—Triamcinolone—psoriasis	4.21e-05	0.000187	CcSEcCtD
Morphine—Anorexia—Methotrexate—psoriasis	4.2e-05	0.000187	CcSEcCtD
Morphine—Urticaria—Prednisone—psoriasis	4.19e-05	0.000186	CcSEcCtD
Morphine—Headache—Triamcinolone—psoriasis	4.18e-05	0.000186	CcSEcCtD
Morphine—Body temperature increased—Prednisone—psoriasis	4.17e-05	0.000186	CcSEcCtD
Morphine—Abdominal pain—Prednisone—psoriasis	4.17e-05	0.000186	CcSEcCtD
Morphine—OPRD1—G alpha (i) signalling events—CXCL8—psoriasis	4.17e-05	0.00132	CbGpPWpGaD
Morphine—UGT1A8—Metabolism—CAT—psoriasis	4.15e-05	0.00131	CbGpPWpGaD
Morphine—OPRK1—Signaling Pathways—TAGAP—psoriasis	4.15e-05	0.00131	CbGpPWpGaD
Morphine—Diarrhoea—Dexamethasone—psoriasis	4.15e-05	0.000184	CcSEcCtD
Morphine—Diarrhoea—Betamethasone—psoriasis	4.15e-05	0.000184	CcSEcCtD
Morphine—Hypotension—Methotrexate—psoriasis	4.12e-05	0.000183	CcSEcCtD
Morphine—OPRM1—Signaling Pathways—HCAR2—psoriasis	4.04e-05	0.00128	CbGpPWpGaD
Morphine—Musculoskeletal discomfort—Methotrexate—psoriasis	4.02e-05	0.000179	CcSEcCtD
Morphine—Dizziness—Betamethasone—psoriasis	4.01e-05	0.000178	CcSEcCtD
Morphine—Dizziness—Dexamethasone—psoriasis	4.01e-05	0.000178	CcSEcCtD
Morphine—Insomnia—Methotrexate—psoriasis	3.99e-05	0.000177	CcSEcCtD
Morphine—Nausea—Triamcinolone—psoriasis	3.97e-05	0.000176	CcSEcCtD
Morphine—Paraesthesia—Methotrexate—psoriasis	3.96e-05	0.000176	CcSEcCtD
Morphine—Dyspnoea—Methotrexate—psoriasis	3.93e-05	0.000175	CcSEcCtD
Morphine—Somnolence—Methotrexate—psoriasis	3.92e-05	0.000174	CcSEcCtD
Morphine—OPRM1—GPCR downstream signaling—CCL20—psoriasis	3.92e-05	0.00124	CbGpPWpGaD
Morphine—Hypersensitivity—Prednisone—psoriasis	3.89e-05	0.000173	CcSEcCtD
Morphine—Dyspepsia—Methotrexate—psoriasis	3.88e-05	0.000173	CcSEcCtD
Morphine—Vomiting—Dexamethasone—psoriasis	3.85e-05	0.000171	CcSEcCtD
Morphine—Vomiting—Betamethasone—psoriasis	3.85e-05	0.000171	CcSEcCtD
Morphine—Decreased appetite—Methotrexate—psoriasis	3.83e-05	0.000171	CcSEcCtD
Morphine—Rash—Betamethasone—psoriasis	3.82e-05	0.00017	CcSEcCtD
Morphine—Rash—Dexamethasone—psoriasis	3.82e-05	0.00017	CcSEcCtD
Morphine—Dermatitis—Dexamethasone—psoriasis	3.82e-05	0.00017	CcSEcCtD
Morphine—Dermatitis—Betamethasone—psoriasis	3.82e-05	0.00017	CcSEcCtD
Morphine—Gastrointestinal disorder—Methotrexate—psoriasis	3.81e-05	0.000169	CcSEcCtD
Morphine—Fatigue—Methotrexate—psoriasis	3.8e-05	0.000169	CcSEcCtD
Morphine—Headache—Betamethasone—psoriasis	3.8e-05	0.000169	CcSEcCtD
Morphine—Headache—Dexamethasone—psoriasis	3.8e-05	0.000169	CcSEcCtD
Morphine—Asthenia—Prednisone—psoriasis	3.79e-05	0.000168	CcSEcCtD
Morphine—Pain—Methotrexate—psoriasis	3.77e-05	0.000168	CcSEcCtD
Morphine—OPRM1—TCR Signaling Pathway—IL6—psoriasis	3.74e-05	0.00118	CbGpPWpGaD
Morphine—Pruritus—Prednisone—psoriasis	3.73e-05	0.000166	CcSEcCtD
Morphine—ABCB1—Allograft Rejection—IFNG—psoriasis	3.73e-05	0.00118	CbGpPWpGaD
Morphine—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	3.72e-05	0.00118	CbGpPWpGaD
Morphine—OPRM1—Peptide ligand-binding receptors—CXCL8—psoriasis	3.66e-05	0.00116	CbGpPWpGaD
Morphine—OPRK1—G alpha (i) signalling events—CXCL8—psoriasis	3.66e-05	0.00116	CbGpPWpGaD
Morphine—OPRL1—Signaling Pathways—SOCS1—psoriasis	3.66e-05	0.00116	CbGpPWpGaD
Morphine—Feeling abnormal—Methotrexate—psoriasis	3.63e-05	0.000162	CcSEcCtD
Morphine—UGT2B15—Metabolism—CAT—psoriasis	3.63e-05	0.00115	CbGpPWpGaD
Morphine—UGT2B4—Metabolism—CAT—psoriasis	3.63e-05	0.00115	CbGpPWpGaD
Morphine—Diarrhoea—Prednisone—psoriasis	3.61e-05	0.000161	CcSEcCtD
Morphine—Gastrointestinal pain—Methotrexate—psoriasis	3.61e-05	0.00016	CcSEcCtD
Morphine—Nausea—Betamethasone—psoriasis	3.6e-05	0.00016	CcSEcCtD
Morphine—Nausea—Dexamethasone—psoriasis	3.6e-05	0.00016	CcSEcCtD
Morphine—OPRM1—Signaling by GPCR—CCL20—psoriasis	3.56e-05	0.00112	CbGpPWpGaD
Morphine—OPRM1—Signaling Pathways—TAGAP—psoriasis	3.51e-05	0.00111	CbGpPWpGaD
Morphine—Urticaria—Methotrexate—psoriasis	3.5e-05	0.000156	CcSEcCtD
Morphine—Dizziness—Prednisone—psoriasis	3.49e-05	0.000155	CcSEcCtD
Morphine—OPRL1—Signaling by GPCR—TYK2—psoriasis	3.49e-05	0.0011	CbGpPWpGaD
Morphine—Abdominal pain—Methotrexate—psoriasis	3.49e-05	0.000155	CcSEcCtD
Morphine—Body temperature increased—Methotrexate—psoriasis	3.49e-05	0.000155	CcSEcCtD
Morphine—ABCB1—Allograft Rejection—CXCL8—psoriasis	3.47e-05	0.0011	CbGpPWpGaD
Morphine—Vomiting—Prednisone—psoriasis	3.36e-05	0.000149	CcSEcCtD
Morphine—OPRL1—GPCR downstream signaling—CXCL8—psoriasis	3.34e-05	0.00106	CbGpPWpGaD
Morphine—Rash—Prednisone—psoriasis	3.33e-05	0.000148	CcSEcCtD
Morphine—Dermatitis—Prednisone—psoriasis	3.32e-05	0.000148	CcSEcCtD
Morphine—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	3.32e-05	0.00105	CbGpPWpGaD
Morphine—Headache—Prednisone—psoriasis	3.31e-05	0.000147	CcSEcCtD
Morphine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	3.25e-05	0.00103	CbGpPWpGaD
Morphine—Hypersensitivity—Methotrexate—psoriasis	3.25e-05	0.000145	CcSEcCtD
Morphine—UGT1A8—Metabolism—APOE—psoriasis	3.23e-05	0.00102	CbGpPWpGaD
Morphine—Asthenia—Methotrexate—psoriasis	3.16e-05	0.000141	CcSEcCtD
Morphine—UGT1A3—Metabolism—CARM1—psoriasis	3.16e-05	0.000999	CbGpPWpGaD
Morphine—Nausea—Prednisone—psoriasis	3.13e-05	0.000139	CcSEcCtD
Morphine—Pruritus—Methotrexate—psoriasis	3.12e-05	0.000139	CcSEcCtD
Morphine—OPRM1—G alpha (i) signalling events—CXCL8—psoriasis	3.09e-05	0.000977	CbGpPWpGaD
Morphine—OPRL1—Signaling by GPCR—CXCL8—psoriasis	3.04e-05	0.000959	CbGpPWpGaD
Morphine—Diarrhoea—Methotrexate—psoriasis	3.02e-05	0.000134	CcSEcCtD
Morphine—Dizziness—Methotrexate—psoriasis	2.92e-05	0.00013	CcSEcCtD
Morphine—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.91e-05	0.000919	CbGpPWpGaD
Morphine—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	2.86e-05	0.000903	CbGpPWpGaD
Morphine—OPRD1—Signaling Pathways—CCL20—psoriasis	2.83e-05	0.000896	CbGpPWpGaD
Morphine—UGT2B4—Metabolism—APOE—psoriasis	2.82e-05	0.000891	CbGpPWpGaD
Morphine—UGT2B15—Metabolism—APOE—psoriasis	2.82e-05	0.000891	CbGpPWpGaD
Morphine—ABCB1—Allograft Rejection—VEGFA—psoriasis	2.82e-05	0.00089	CbGpPWpGaD
Morphine—UGT1A8—Metabolism—PPARG—psoriasis	2.81e-05	0.000888	CbGpPWpGaD
Morphine—Vomiting—Methotrexate—psoriasis	2.8e-05	0.000125	CcSEcCtD
Morphine—Rash—Methotrexate—psoriasis	2.78e-05	0.000124	CcSEcCtD
Morphine—Dermatitis—Methotrexate—psoriasis	2.78e-05	0.000124	CcSEcCtD
Morphine—CYP2C8—Metabolism—NDUFA5—psoriasis	2.77e-05	0.000875	CbGpPWpGaD
Morphine—Headache—Methotrexate—psoriasis	2.76e-05	0.000123	CcSEcCtD
Morphine—OPRL1—Signaling Pathways—LEP—psoriasis	2.7e-05	0.000853	CbGpPWpGaD
Morphine—OPRL1—Signaling Pathways—APOE—psoriasis	2.7e-05	0.000853	CbGpPWpGaD
Morphine—UGT2B7—Metabolism—CARM1—psoriasis	2.69e-05	0.000849	CbGpPWpGaD
Morphine—Nausea—Methotrexate—psoriasis	2.62e-05	0.000117	CcSEcCtD
Morphine—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.58e-05	0.000816	CbGpPWpGaD
Morphine—OPRD1—GPCR ligand binding—CXCL8—psoriasis	2.53e-05	0.000798	CbGpPWpGaD
Morphine—OPRL1—Signaling Pathways—NFKBIA—psoriasis	2.51e-05	0.000795	CbGpPWpGaD
Morphine—OPRK1—Signaling Pathways—CCL20—psoriasis	2.49e-05	0.000785	CbGpPWpGaD
Morphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.46e-05	0.000776	CbGpPWpGaD
Morphine—UGT2B4—Metabolism—PPARG—psoriasis	2.46e-05	0.000776	CbGpPWpGaD
Morphine—UGT2B15—Metabolism—PPARG—psoriasis	2.46e-05	0.000776	CbGpPWpGaD
Morphine—ABCB1—Allograft Rejection—TNF—psoriasis	2.41e-05	0.000763	CbGpPWpGaD
Morphine—ABCB1—Metabolism—NDUFA5—psoriasis	2.41e-05	0.000763	CbGpPWpGaD
Morphine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	2.4e-05	0.000758	CbGpPWpGaD
Morphine—CYP2C8—Metabolism—CYP2S1—psoriasis	2.36e-05	0.000744	CbGpPWpGaD
Morphine—CYP2D6—Metabolism—NDUFA5—psoriasis	2.27e-05	0.000719	CbGpPWpGaD
Morphine—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	2.24e-05	0.000709	CbGpPWpGaD
Morphine—OPRK1—GPCR ligand binding—CXCL8—psoriasis	2.21e-05	0.0007	CbGpPWpGaD
Morphine—UGT1A1—Metabolism—CARM1—psoriasis	2.18e-05	0.00069	CbGpPWpGaD
Morphine—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	2.14e-05	0.000676	CbGpPWpGaD
Morphine—OPRM1—Signaling Pathways—CCL20—psoriasis	2.1e-05	0.000664	CbGpPWpGaD
Morphine—OPRL1—Signaling Pathways—TYK2—psoriasis	2.06e-05	0.000651	CbGpPWpGaD
Morphine—ABCB1—Metabolism—CYP2S1—psoriasis	2.05e-05	0.000648	CbGpPWpGaD
Morphine—UGT1A3—Metabolism—CAT—psoriasis	1.94e-05	0.000614	CbGpPWpGaD
Morphine—CYP2D6—Metabolism—CYP2S1—psoriasis	1.93e-05	0.000611	CbGpPWpGaD
Morphine—OPRM1—GPCR ligand binding—CXCL8—psoriasis	1.87e-05	0.000591	CbGpPWpGaD
Morphine—OPRL1—Signaling Pathways—CXCL8—psoriasis	1.79e-05	0.000567	CbGpPWpGaD
Morphine—OPRL1—Signaling by GPCR—IL6—psoriasis	1.71e-05	0.000539	CbGpPWpGaD
Morphine—OPRL1—Signaling Pathways—JUN—psoriasis	1.67e-05	0.000527	CbGpPWpGaD
Morphine—UGT2B7—Metabolism—CAT—psoriasis	1.65e-05	0.000522	CbGpPWpGaD
Morphine—OPRL1—Signaling Pathways—NFKB1—psoriasis	1.6e-05	0.000507	CbGpPWpGaD
Morphine—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.59e-05	0.000503	CbGpPWpGaD
Morphine—OPRD1—Signaling Pathways—SOCS1—psoriasis	1.56e-05	0.000493	CbGpPWpGaD
Morphine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.53e-05	0.000484	CbGpPWpGaD
Morphine—UGT1A3—Metabolism—APOE—psoriasis	1.51e-05	0.000477	CbGpPWpGaD
Morphine—OPRD1—Signaling by GPCR—TYK2—psoriasis	1.49e-05	0.00047	CbGpPWpGaD
Morphine—CYP3A4—Metabolism—NDUFA5—psoriasis	1.49e-05	0.00047	CbGpPWpGaD
Morphine—OPRL1—Signaling Pathways—VEGFA—psoriasis	1.46e-05	0.00046	CbGpPWpGaD
Morphine—OPRL1—Signaling Pathways—STAT3—psoriasis	1.44e-05	0.000456	CbGpPWpGaD
Morphine—OPRD1—GPCR downstream signaling—CXCL8—psoriasis	1.43e-05	0.000451	CbGpPWpGaD
Morphine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.39e-05	0.000439	CbGpPWpGaD
Morphine—OPRK1—Signaling Pathways—SOCS1—psoriasis	1.37e-05	0.000432	CbGpPWpGaD
Morphine—UGT1A1—Metabolism—CAT—psoriasis	1.34e-05	0.000425	CbGpPWpGaD
Morphine—UGT1A3—Metabolism—PPARG—psoriasis	1.32e-05	0.000416	CbGpPWpGaD
Morphine—OPRK1—Signaling by GPCR—TYK2—psoriasis	1.31e-05	0.000412	CbGpPWpGaD
Morphine—OPRD1—Signaling by GPCR—CXCL8—psoriasis	1.3e-05	0.000409	CbGpPWpGaD
Morphine—UGT2B7—Metabolism—APOE—psoriasis	1.28e-05	0.000406	CbGpPWpGaD
Morphine—CYP3A4—Metabolism—CYP2S1—psoriasis	1.26e-05	0.000399	CbGpPWpGaD
Morphine—OPRK1—GPCR downstream signaling—CXCL8—psoriasis	1.25e-05	0.000395	CbGpPWpGaD
Morphine—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.23e-05	0.00039	CbGpPWpGaD
Morphine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.19e-05	0.000376	CbGpPWpGaD
Morphine—OPRM1—Signaling Pathways—SOCS1—psoriasis	1.16e-05	0.000366	CbGpPWpGaD
Morphine—OPRD1—Signaling Pathways—LEP—psoriasis	1.15e-05	0.000364	CbGpPWpGaD
Morphine—OPRD1—Signaling Pathways—APOE—psoriasis	1.15e-05	0.000364	CbGpPWpGaD
Morphine—CYP2C8—Metabolism—CARM1—psoriasis	1.15e-05	0.000363	CbGpPWpGaD
Morphine—OPRK1—Signaling by GPCR—CXCL8—psoriasis	1.14e-05	0.000359	CbGpPWpGaD
Morphine—UGT2B7—Metabolism—PPARG—psoriasis	1.12e-05	0.000354	CbGpPWpGaD
Morphine—OPRM1—Signaling by GPCR—TYK2—psoriasis	1.1e-05	0.000348	CbGpPWpGaD
Morphine—OPRL1—Signaling Pathways—TP53—psoriasis	1.1e-05	0.000348	CbGpPWpGaD
Morphine—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.08e-05	0.00034	CbGpPWpGaD
Morphine—OPRD1—Signaling Pathways—NFKBIA—psoriasis	1.07e-05	0.000339	CbGpPWpGaD
Morphine—OPRM1—GPCR downstream signaling—CXCL8—psoriasis	1.06e-05	0.000334	CbGpPWpGaD
Morphine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.05e-05	0.000332	CbGpPWpGaD
Morphine—UGT1A1—Metabolism—APOE—psoriasis	1.04e-05	0.00033	CbGpPWpGaD
Morphine—OPRK1—Signaling Pathways—LEP—psoriasis	1.01e-05	0.000319	CbGpPWpGaD
Morphine—OPRK1—Signaling Pathways—APOE—psoriasis	1.01e-05	0.000319	CbGpPWpGaD
Morphine—OPRL1—Signaling Pathways—IL6—psoriasis	1.01e-05	0.000318	CbGpPWpGaD
Morphine—ABCB1—Metabolism—CARM1—psoriasis	1e-05	0.000317	CbGpPWpGaD
Morphine—OPRM1—Signaling by GPCR—CXCL8—psoriasis	9.6e-06	0.000303	CbGpPWpGaD
Morphine—CYP2D6—Metabolism—CARM1—psoriasis	9.44e-06	0.000298	CbGpPWpGaD
Morphine—OPRK1—Signaling Pathways—NFKBIA—psoriasis	9.41e-06	0.000297	CbGpPWpGaD
Morphine—UGT1A1—Metabolism—PPARG—psoriasis	9.09e-06	0.000287	CbGpPWpGaD
Morphine—OPRD1—Signaling Pathways—TYK2—psoriasis	8.79e-06	0.000278	CbGpPWpGaD
Morphine—OPRM1—Signaling Pathways—LEP—psoriasis	8.54e-06	0.00027	CbGpPWpGaD
Morphine—OPRM1—Signaling Pathways—APOE—psoriasis	8.54e-06	0.00027	CbGpPWpGaD
Morphine—OPRM1—Signaling Pathways—NFKBIA—psoriasis	7.95e-06	0.000251	CbGpPWpGaD
Morphine—OPRK1—Signaling Pathways—TYK2—psoriasis	7.71e-06	0.000244	CbGpPWpGaD
Morphine—OPRD1—Signaling Pathways—CXCL8—psoriasis	7.65e-06	0.000242	CbGpPWpGaD
Morphine—OPRD1—Signaling by GPCR—IL6—psoriasis	7.28e-06	0.00023	CbGpPWpGaD
Morphine—OPRD1—Signaling Pathways—JUN—psoriasis	7.12e-06	0.000225	CbGpPWpGaD
Morphine—CYP2C8—Metabolism—CAT—psoriasis	7.08e-06	0.000224	CbGpPWpGaD
Morphine—OPRD1—Signaling Pathways—NFKB1—psoriasis	6.85e-06	0.000216	CbGpPWpGaD
Morphine—OPRK1—Signaling Pathways—CXCL8—psoriasis	6.71e-06	0.000212	CbGpPWpGaD
Morphine—OPRM1—Signaling Pathways—TYK2—psoriasis	6.52e-06	0.000206	CbGpPWpGaD
Morphine—OPRK1—Signaling by GPCR—IL6—psoriasis	6.38e-06	0.000202	CbGpPWpGaD
Morphine—OPRK1—Signaling Pathways—JUN—psoriasis	6.24e-06	0.000197	CbGpPWpGaD
Morphine—OPRD1—Signaling Pathways—VEGFA—psoriasis	6.22e-06	0.000196	CbGpPWpGaD
Morphine—CYP3A4—Metabolism—CARM1—psoriasis	6.17e-06	0.000195	CbGpPWpGaD
Morphine—ABCB1—Metabolism—CAT—psoriasis	6.16e-06	0.000195	CbGpPWpGaD
Morphine—OPRD1—Signaling Pathways—STAT3—psoriasis	6.16e-06	0.000195	CbGpPWpGaD
Morphine—OPRK1—Signaling Pathways—NFKB1—psoriasis	6.01e-06	0.00019	CbGpPWpGaD
Morphine—CYP2D6—Metabolism—CAT—psoriasis	5.81e-06	0.000184	CbGpPWpGaD
Morphine—OPRM1—Signaling Pathways—CXCL8—psoriasis	5.67e-06	0.000179	CbGpPWpGaD
Morphine—CYP2C8—Metabolism—APOE—psoriasis	5.5e-06	0.000174	CbGpPWpGaD
Morphine—OPRK1—Signaling Pathways—VEGFA—psoriasis	5.45e-06	0.000172	CbGpPWpGaD
Morphine—OPRK1—Signaling Pathways—STAT3—psoriasis	5.4e-06	0.000171	CbGpPWpGaD
Morphine—OPRM1—Signaling by GPCR—IL6—psoriasis	5.39e-06	0.00017	CbGpPWpGaD
Morphine—OPRM1—Signaling Pathways—JUN—psoriasis	5.27e-06	0.000167	CbGpPWpGaD
Morphine—OPRM1—Signaling Pathways—NFKB1—psoriasis	5.08e-06	0.00016	CbGpPWpGaD
Morphine—ABCB1—Metabolism—APOE—psoriasis	4.79e-06	0.000151	CbGpPWpGaD
Morphine—CYP2C8—Metabolism—PPARG—psoriasis	4.79e-06	0.000151	CbGpPWpGaD
Morphine—OPRD1—Signaling Pathways—TP53—psoriasis	4.7e-06	0.000148	CbGpPWpGaD
Morphine—OPRM1—Signaling Pathways—VEGFA—psoriasis	4.61e-06	0.000146	CbGpPWpGaD
Morphine—OPRM1—Signaling Pathways—STAT3—psoriasis	4.56e-06	0.000144	CbGpPWpGaD
Morphine—CYP2D6—Metabolism—APOE—psoriasis	4.51e-06	0.000143	CbGpPWpGaD
Morphine—OPRD1—Signaling Pathways—IL6—psoriasis	4.3e-06	0.000136	CbGpPWpGaD
Morphine—ABCB1—Metabolism—PPARG—psoriasis	4.17e-06	0.000132	CbGpPWpGaD
Morphine—OPRK1—Signaling Pathways—TP53—psoriasis	4.12e-06	0.00013	CbGpPWpGaD
Morphine—CYP2D6—Metabolism—PPARG—psoriasis	3.93e-06	0.000124	CbGpPWpGaD
Morphine—CYP3A4—Metabolism—CAT—psoriasis	3.8e-06	0.00012	CbGpPWpGaD
Morphine—OPRK1—Signaling Pathways—IL6—psoriasis	3.77e-06	0.000119	CbGpPWpGaD
Morphine—OPRM1—Signaling Pathways—TP53—psoriasis	3.48e-06	0.00011	CbGpPWpGaD
Morphine—OPRM1—Signaling Pathways—IL6—psoriasis	3.19e-06	0.000101	CbGpPWpGaD
Morphine—CYP3A4—Metabolism—APOE—psoriasis	2.95e-06	9.32e-05	CbGpPWpGaD
Morphine—CYP3A4—Metabolism—PPARG—psoriasis	2.57e-06	8.12e-05	CbGpPWpGaD
